Theratechnologies Email Format

Pharmaceutical ManufacturingQuebec, Canada51-200 Employees

Theratechnologies is a specialty pharmaceutical company focused on discovering and developing peptide-based therapies, with an emphasis on growth-hormone releasing factor (GRF) peptides. The company aims to apply its metabolism and GRF expertise to address serious health disorders while pursuing commercialization of its future products. Its first product, EGRIFTA (tesamorelin for injection), was approved by the U.S. FDA in November 2010 and is the only approved therapy for reducing excess abdominal fat in people living with HIV. Based in Saint-Laurent, Quebec, Theratechnologies operates in the pharmaceutical manufacturing sector as a commercial-stage company. In September 2025, the company announced the completion of a plan of arrangement to be acquired by CB Biotechnology, an affiliate of Future Pak. The arrangement received final court approval and shareholder approval.

Sign up for free to view info

Company overview Employee directory